Figure 5 by Parvin Shahrestani (260210)

“…<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0006867#pone-0006867-g005" target="_blank">Figure 5B</a>. The decreased heart rate shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0006867#pone-0006867-g005" target="_blank">Figure 5A</a> was predominantly due to an increase in diastolic intervals (<0.001), not an increase in systolic intervals (0.09).…”

IGF-1 injections significantly attenuate the increase in CD4+CD8+ double positive T cells seen at day 30 after IR. by Jordan A. Gunning (18143970)

Figure 5 by Collins Assisi (316086)

“…<p><b>a.</b> The mean Euclidean distance between the representations of similar odors shown as a function of lateral excitation and slow inhibition. …”

IGF-1 injections significantly attenuate the increase in macrophages and neutrophils observed at day 30 following IR. by Jordan A. Gunning (18143970)

Presentation1_Are the 50 m Race Segments Changed From Heats to Finals at the 2021 European Swimming Championships?.PDF by Raúl Arellano (13036584)

“…Specifically, combining men and women, the swimmers had in freestyle a mean coefficient of variation (CV) of ∼0.6%, with a mean range of performance improvement (∆%) of ∆ = ∼0.7%; in breaststroke a mean CV of ∼0.5% and ∆ = −0.2%; in backstroke a mean CV of ∼0.5% and ∆ = −0.6%, and; in butterfly a mean CV of ∼0.7% and ∆ = −0.9%. …”

Fig 4 - by Hyuk Sung Yoon (20208672)

Characteristics of treatment modality. by Adekunle Emmanuel Sajo (15285520)

“…The median time to completion of radiotherapy treatment was higher among those who received primary radiotherapy as compared to those who received adjuvant treatment, 51.5 vs 46 days, p 0.039. The annual average age decreased from 56 years to as low as 40 years, a mean difference of 16 years, p 0.012.…”

Demographic and clinical characteristics. by Adekunle Emmanuel Sajo (15285520)

“…The median time to completion of radiotherapy treatment was higher among those who received primary radiotherapy as compared to those who received adjuvant treatment, 51.5 vs 46 days, p 0.039. The annual average age decreased from 56 years to as low as 40 years, a mean difference of 16 years, p 0.012.…”

Effects of antenatal DEX treatment on claudin-5 expression in total brains and brain endothelial fractions at PN4 and PN10 pups. by Winfried Neuhaus (513628)

Mitochondrial replication machinery. by Kaytee L. Pokrzywinski (3605435)

Poly(ionic liquid) Electrolytes for a Switchable Silver Mirror by Xiao Hou (3228048)

“…These findings were used to guide fabrication of a 50 cm² mirror dynamic window and flexible display. …”

mtDNA gene expression and stability. by Kaytee L. Pokrzywinski (3605435)

DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet6_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet4_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

Data_Sheet_1_Propofol EC50 for inducing loss of consciousness in patients under combined epidural-general anesthesia or general anesthesia alone: a randomized double-blind study.do... by Jiangling Wang (11929476)

“…</p>Conclusion<p>Concomitant epidural anesthesia reduced by 15% the EC₅₀ of predicted Ce_prop for LOC, decreased the consumptions of propofol and remifentanil during maintenance of anesthesia, and fastened recovery from anesthesia.…”

Example for a parametrically manipulated baby. by Sarah K. C. Holtfrerich (3353693)